SCHEMBL22979896

SCHEMBL22979896

N#Cc1cccc(Cl)c1NC(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 6/20 0.43
KDM4E B2RXH2 5/20 0.43
ALDH1A1 P00352 5/20 0.43
HPGD P15428 2/20 0.43
TAS1R3 Q7RTX0 1/20 0.43
TAS1R1 Q7RTX1 1/20 0.43
TAS1R2 Q8TE23 1/20 0.43
MEN1 O00255 3/20 0.41
LMNA P02545 3/20 0.41
KMT2A Q03164 3/20 0.41
ALOX15 P16050 2/20 0.41
HSD17B10 Q99714 2/20 0.41
CXCR2 P25025 1/20 0.41
GLA P06280 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
MAPT P10636 1/20 0.40
GFER P55789 1/20 0.40
PTK2B Q14289 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30320184 0.85 ALDH1A1 (0.43) GAAKDM4EALDH1A1HPGDTAS1R3
SCHEMBL2093660 0.81 MEN1 (0.56) MEN1LMNAKMT2AL3MBTL1MAPT
SCHEMBL22979609 0.81 TSHR (0.48) GAAKDM4EALDH1A1MEN1LMNA
SCHEMBL29649048 0.81 NLRP3 (0.60) GAAKDM4EALDH1A1HPGDLMNA
SCHEMBL22987863 0.81 NLRP3 (0.60) GAAKDM4EALDH1A1HPGDLMNA
SCHEMBL30542552 0.81 KMT2A (0.48) GAAKDM4EALDH1A1HPGDMEN1
SCHEMBL22979056 0.79 GAA (0.41) GAAKDM4EALDH1A1MEN1LMNA
SCHEMBL21995607 0.79 KMT2A (0.45) GAAKDM4EALDH1A1MEN1LMNA
SCHEMBL25373430 0.79 MAPK1 (0.55) GAAKDM4EALDH1A1HPGDMEN1
SCHEMBL11579842 0.77 GAA (0.40) GAAKDM4EALDH1A1HPGDTAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023158626-A1 ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE THEREOF MERCK SHARP & DOHME LLC (US) 2023-08-24 WO disclosed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 GAA 3740/4885KDM4E 1364/4885ALDH1A1 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.